Beijing Wantai Biological Pharmacy Enterprise Co Ltd

603392

Company Profile

  • Business description

    Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.

  • Contact

    No. 31, Science Park Road
    Changping District
    Beijing102206
    CHN

    T: +86 1059528888

    https://www.ystwt.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4,116

Stocks News & Analysis

stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks

ASX energy share remains cheap despite strong outlook

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks

Moated AI-proof tech play hiding in the ASX 100

ChatGPT and large language models should be a tailwind for this company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.4019.00-0.21%
CAC 408,157.8269.50-0.84%
DAX 4024,128.9826.47-0.11%
Dow JONES (US)49,230.7179.61-0.16%
FTSE 10010,379.0877.93-0.75%
HKSE25,978.0762.870.24%
NASDAQ24,836.60398.101.63%
Nikkei 22559,716.18575.950.97%
NZX 50 Index12,874.949.99-0.08%
S&P 5007,165.0856.680.80%
S&P/ASX 2008,786.5012.10-0.14%
SSE Composite Index4,079.9013.35-0.33%

Market Movers